Investor Presentation

October 30, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai-400001 Complex, Bandra (East), Mumbai-400051 (Scrip Code: 544644) (SYMBOL: CORONA) Dear Sir / Madam, Sub.: Presentation to Analyst / Investor In continuation to our letter dated October 16, 2026 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the investor presentation on the performance of the Company for the second quarter and half year ended September 30, 2026. You are requested to take note of the above. Thanking you. Yours faithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer Encl.: A/a CORONA Remedies Limited Investor Presentation: October 2026 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by CORONA Remedies Limited (the “Company”), have beenpreparedsolelyforinformationpurposesanddonotconstituteanyoffer,recommendationorinvitationtopurchaseorsubscribeforanysecurities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the CompanywillbemadeexceptbymeansofastatutoryofferingdocumentcontainingdetailedinformationabouttheCompany. ThisPresentationhasbeenpreparedbytheCompanybasedoninformationanddatawhichtheCompanyconsidersreliable,buttheCompanymakesno representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness ofthecontentsof this Presentation.This Presentationmay notbe allinclusiveandmaynotcontainallof theinformationthatyoumay considermaterial.Anyliabilityinrespectofthecontentsof,oranyomissionfrom,thisPresentationisexpresslyexcluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation,changes andadvancements,changesinrevenue,incomeorcashflows,theCompany’smarketpreferences anditsexposuretomarket risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Anyforward-lookingstatements and projectionsmade by thirdpartiesincluded inthis Presentation are not adopted by the Company and theCompanyisnotresponsibleforsuchthird-partystatements andprojections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy,timelinessorcompleteness Contents Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY27 About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Annexures Management Team and Historical Financial Performance Key Highlights for Q2 & H1 FY27 Financial Highlights Return Ratios Key Highlights Q2FY27 (Y-o-Y) H1 FY27 (Y-o-Y) H1 FY27  India business contributed 97.1% of total revenueinH1FY27. INR 441.2 Cr INR 863.6 Cr 49.8%  Chronic and sub-chronic therapies REVENUE contribute ~72.1% inH1FY27. + 22.2% +22.0% ROCE#  Improved our Rank to 26th in MAT Sep-26 from 27th in MAT Mar-26 in INR 96.0 Cr INR 189.1 Cr  Renewed EU-GMP certification for 32.9% the Oral Solid Dosage line at Bhayla EBITDA + 22.3% +27.5% plant inMay 2026. ROE# 21.7% EBITDA Margin 21.9% EBITDA Margin  Inaugurated Hormone Facility at Bhayla with EU-GMP certification in June2026. INR 60.3 Cr INR 120.4 Cr  Received ANVISA GMP (Brazil) ₹19.7/- Certification for Bhayla OSD & PAT +15.3% +22.2% Hormone Manufacturing Facility in EPS* October 2026. 13.7% PAT Margin 13.9% PAT Margin #Annualised *Not Annualised [1] Pharmatrac 4 Q2 & H1FY27 Consolidated Profit & Loss Statement Profit and Loss (INR Crores) Q2FY27 Q2FY26 Y-o-Y H1FY27 H1FY26 Y-o-Y Revenue from Operations 441.2 361.1 22.2% 863.6 707.7 22.0% Gross Margin (%) 81.8% 81.0% 81.7% 81.0% Employee Cost 124.2 103.0 246.3 200.4 Other Expenses 140.5 111.0 270.2 224.6 EBITDA 96.0 78.5 22.3% 189.1 148.2 27.5% EBITDA Margin (%) 21.7% 21.7% 21.9% 20.9% Depreciation & Amortization 15.1 9.2 28.3 18.1 Other Income 2.5 2.3 5.6 4.3 Finance Cost 2.8 1.9 5.4 3.9 Share in Profit/(loss) in Associate 0.1 0.2 0.1 -0.0 Profit before Tax 80.8 69.8 161.1 130.5 Tax Expense 20.4 17.5 40.7 32.0 Profit After Tax(PAT) * 60.3 52.3 15.3% 120.4 98.5 22.2% PAT Margin (%)* 13.7% 14.5% 13.9% 13.9% *PAT&PATMarginwaslowerinQ2duetohigherdepreciation&amortizationforournewlycommissionedfacilitiesandacquisitionofbrands. Consolidated Balance Sheet Assets (INR Crores) Sep-26 Mar-26 Equity & Liabilities (INR Crores) Sep-26 Mar-26 Non -Current Assets 773.1 856.8 Total Equity 805.1 746.9 Property, plant and equipment 425.2 291.1 Share Capital 61.2 61.2 Capital work-in-progress 21.8 143.1 Other Equity 744.0 685.7 Intangible assets 246.9 262.8 Non-Current Liabilities 108.6 97.1 Investments accounted as per equity method 26.3 26.1 Financial Assets Financial Liabilities Investments 0.2 0.2 Borrowings 0.3 0.0 Other Financial Assets 50.9 129.9 Provisions 75.4 66.1 Loans 0.0 0.0 Deferred tax liabilities (net) 15.7 12.2 Other non-current assets 1.8 3.6 Lease Liabilities 17.3 18.9 Current Assets 473.7 348.3 Current Liabilities 333.0 361.2 Inventories 170.7 125.0 Financial Liabilities Financial Assets (i) Borrowings* 94.3 142.9 (i)Trade receivables 170.6 145.6 (ii) Trade Payables 115.7 90.3 (ii)Cash and cash equivalents 1.6 1.8 (iii) Other Financial Liabilities 64.0 76.5 (iii)Bank balances 97.2 42.3 Other Current Liabilities 8.4 7.0 Loans 0.1 0.3 Lease Liabilities 3.3 3.1 Other Financial Assets 0.1 0.3 Current Tax Liabilities 11.7 8.4 Other Current Assets 33.4 33.1 Provisions 35.7 33.0 Total Assets 1,246.7 1,205.1 Total Equity & Liabilities 1,246.7 1,205.1 * Short Term Borrowings includes Overdraft against Fixed Deposit shown under Other Financial Assets & Bank Balances (FD –146.8Cr & OD –94.3 Cr) Consolidated Abridged Cash Flow Statement Particulars (INR Crores) H1FY27 H1FY26 Profit Before Tax 161.1 130.5 Adjustments for: Non -Cash Items / Other Investment or Financial Items 33.7 23.3 Operating profit before working capital changes 194.8 153.8 Changes in working capital -48.6 -17.7 Cash generated from Operations 146.3 136.0 Income taxes paid (net) -33.5 -22.6 Net Cash from Operating Activities 112.7 113.4 Net Cash from Investing Activities 3.3 -41.3 Net Cash from Financing Activities -116.3 -73.6 Net Increase/(Decrease) in Cash and Cash equivalents -0.2 -1.4 Add: Cash & Cash equivalents at the beginning of the period 1.8 3.2 Cash & Cash equivalents at the end of the period 1.6 1.8 Net Debt / (Cash) (53.9) (40.4) Contents About us Overview of CORONA CORONA: Outpacing IPM Growth CORONA vs. IPM Focused Brand Building Approach Strong brand recall across Therapeutic Areas Road Ahead Key Growth Strategies Operational & Financial Performance Financial & Operational Performance for Q2 and H1 FY27 Annexures [Showing first 8,000 characters — download PDF for full document]